- Scheme Category:
- Equity Scheme >
NAV: ₹ 628.4076 ↓ -0.29%
[as on 1 October, 2026]
NAV chart
SMA (Simple Moving Average)
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 1 October, 2026
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 | Sep 2026 |
|---|
| Returns | -1.24% | -4.66% | 5.31% | -4.85% | 6.03% | 2.37% | 5.46% | 2.71% | 2.06% | -2.68% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|
| Returns | 13.6% | 4.41% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|
| 97.99% |
0.00% (Arbitrage: 0.00%) |
0.00% |
0.00% |
2.01% |
Equity
Portfolio data is as on date 31 August, 2026
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV | % change |
|---|
| 1 October, 2026 | 628.4076 | -0.29% |
| 30 September, 2026 | 630.2169 | -1.69% |
| 29 September, 2026 | 641.0190 | 0.24% |
| 28 September, 2026 | 639.5116 | -0.8% |
| 25 September, 2026 | 644.6841 | -0.36% |
| 24 September, 2026 | 647.0082 | -0.55% |
| 23 September, 2026 | 650.6031 | 0.62% |
| 22 September, 2026 | 646.5722 | -0.43% |
| 21 September, 2026 | 649.3465 | 0.87% |
| 18 September, 2026 | 643.7329 | 0.87% |
| 17 September, 2026 | 638.1725 | 1.21% |
| 16 September, 2026 | 630.5186 | -0.26% |
| 15 September, 2026 | 632.1723 | -0.97% |
| 11 September, 2026 | 638.3641 | -0.22% |
| 10 September, 2026 | 639.7674 | -0.56% |
| 9 September, 2026 | 643.4016 | -0.34% |
| 8 September, 2026 | 645.5743 | 0.31% |
| 7 September, 2026 | 643.5936 | 0.24% |
| 4 September, 2026 | 642.0816 | -0.57% |
| 3 September, 2026 | 645.7740 | -0.17% |
| 2 September, 2026 | 646.8638 | -0.11% |
| 1 September, 2026 | 647.5641 | -0.93% |
| 31 August, 2026 | 653.6135 | 0.61% |
| 28 August, 2026 | 649.6782 | 0.2% |
| 27 August, 2026 | 648.4050 | 0.13% |
| 26 August, 2026 | 647.5412 | 0.46% |
| 25 August, 2026 | 644.5844 | 0.45% |
| 24 August, 2026 | 641.6881 | -0.19% |
| 21 August, 2026 | 642.8931 | 0.09% |
| 20 August, 2026 | 642.2898 | |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 628.4076 as on 1 October, 2026.
What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 10.34% as on 1 October, 2026.
What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 12.36% as on 1 October, 2026.
What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 17.62% as on 1 October, 2026.
What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.51% as on 1 October, 2026.
What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.51% as on 1 October, 2026.
What are top 10 holdings of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
Top 10 holdings of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are:
- Sun Pharmaceutical Industries Limited
- Divi's Laboratories Limited
- Lupin Limited
- Cipla Limited
- Apollo Hospitals Enterprise Limited
- Dr. Reddy's Laboratories Limited
- Mankind Pharma Limited
- Sai Life Sciences Limited
- Ajanta Pharma Limited
- GlaxoSmithKline Pharmaceuticals Limited
- Max Healthcare Institute Limited
What is LTCG (Long term capital gain) and STCG (Short term capital gain) tax for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is equity oriented mutual fund. Various capital gain taxes are applicable as below (Effective for redemption after July 23, 2024 and from FY 2024-25)
| Holding period | Tax rate |
|---|
| Less than 1 year (STCG) | 20% |
| More than 1 year (LTCG) | Tax free upto Rs. 1.25 lakhs. 12.5% on rest amount. |